FDA denies Alimera eye drug; Napo Pharma ends Salix collaboration;

 @FierceBiotech: We have another new Fierce addition! Please say hello to @MarkHfierce, who will be covering drug delivery, biotech research and more. News | Follow @FierceBiotech

 @JohnCFierce: So Verastem has now raised $68M in VC cash; spent $8.5M and wants a $50M IPO. Sure. Article | Follow @JohnCFierce

 @RyanMFierce: After what's happened at $DNDN, folks will look very carefully at next crop of cancer vax developers like NewLink. | Follow @RyanMFierce

 @MaureenFierce: Reading: Resveratrol in humans: Results of a controlled trial. Blog entry | Follow @MaureenFierce

> The FDA has opted to not approve Alimera's ($ALIM) application for its eye drug Iluvien for treating diabetic macular edema. News of the agency's Complete Response Letter prompted a selloff of Alimera stock and that of pSivida ($PSDV), which provides the drug delivery tech for the experimental eye drug. Alimera release

> Napo Pharmaceuticals said that it has nixed its collaboration agreement with Salix Pharmaceuticals related to Napo's developmental diarrhea candidate crofelemer. Item

> Venture capitalist Bruce Booth gives his take on the facts and fictions associated with "virtual biotechs," which has been favored as a limber model for advancing drugs. Blog post

> New York Blood Center has garnered the first FDA approval for its hematopoietic progenitor cells-cord cell therapy used in the treatment of cancer patients. Update

> Affymax has received $13 million in its settlement with Janssen Biotech related to a patent on peginesatide. Report

> Florida's Vaccine and Gene Therapy Institute (VGTI) has spun off a new upstart called TomegaVax to advance vaccines technology that could be useful in providing new attacks against HIV, tuberculosis and hepatitis C. Interview

Pharma News

 @FiercePharma: Are the best times for Big Pharma in China already over? Or will volume make up for new price cuts? BloombergArticle | Follow @FiercePharma

> Analysts handicap Ranbaxy's Lipitor copycat. Report

> Less cash, more promises in pay-to-delay deals. Story

> Teva: 'Too early' to say whether merger triggers job cuts. Report

> IntelGenx antidepressant gets FDA nod, but no launch yet. Item

> Aggressive pricing tarnishes China's promise to pharma. News

> Doxil shortage drags on, with J&J exec citing 'limited options.' Story

And Finally... We salute our nation's military veterans today. Thank you for your sacrifices.

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.